Fulgent Genetics (FLGT) Operating Leases (2019 - 2026)

Fulgent Genetics has reported Operating Leases for 7 years, with the latest figure at $5.6 million in Q2 2026.

• Quarterly Operating Leases rose 48.98% year-over-year to $5.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.6 million (up 48.98% YoY) and the FY2025 annual result came in at $3.8 million, down 8.23% from the prior year.
• Operating Leases eased to $5.6 million in Q2 2026 per FLGT's latest filing, from $6.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $8.8 million in Q4 2022 and troughed at $3.6 million in Q3 2025.
• A 5-year average of $5.4 million and a median of $5.1 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2025 and 2026: Operating Leases slumped 47.38% in 2025, then jumped 54.33% in 2026.
• Over 5 years, Operating Leases stood at $8.8 million in 2022, then slipped by 18.74% to $7.1 million in 2023, then slumped by 42.35% to $4.1 million in 2024, then retreated by 8.23% to $3.8 million in 2025, then surged by 48.35% to $5.6 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $5.6 million, $6.0 million, and $3.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.